Serum and glucocorticoid inducible protein kinases(SGKs):a potential target for cancer intervention

作     者：Rajesh Basnet Grace Qun Gong Chenyao Li Ming-Wei Wang 

作者机构：The National Center for Drug Screening and the CAS Key Laboratory of Receptor Research Shanghai Institute of Materia MedicaChinese Academy of Sciences (CAS) University of Chinese Academy of Sciences Department of Molecular Medicine and Pathology The University of Auckland School of Pharmacy Fudan University 

出 版 物：《Acta Pharmaceutica Sinica B》 (药学学报（英文版）)

年 卷 期：2018年第8卷第5期

页      面：767-771页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1001[医学-基础医学(可授医学、理学学位)] 10[医学] 

基　　金：supported by grants from the Ministry of Science and Technology of China (2014DFG32200) Shanghai Science and Technology Development Fund (15DZ2291600) the Thousand Talents Program in China (166) 

主　　题：SGK AKT PI3K Cancer Signalling Kinase Inhibitor 

摘      要：The serum and glucocorticoid inducible protein kinase(SGK) family members share similar structure, substrate specificity and function with AKT and signal downstream of the phosphatidylinositol 3-kinase(PI3K) signalling pathway. They regulate a range of fundamental cellular processes such as cell proliferation and survival, thereby playing an important role in cancer development. This perspective intends to give an overview on the involvement of SGKs(particularly SGK3) in cancer progression, and compares the actions of SGK3 and AKT in cell cycle regulation, oncogenic signalling, and the potential as a therapeutic target for cancer.